The purpose of the study was to evaluate the immunogenicity and describe the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal polysaccharide groups A, C, W-135 and Y (Nimenrix®) Conjugate vaccine in toddlers 12 to 23 months of age in the European Union (EU). The toddlers were either meningococcal vaccine naïve or had received monovalent meningococcal C (MenC) vaccination during infancy to evaluate any potential impact of the meningococcal vaccine background on the immunogenicity and safety profile of the investigational product.
Primary Objectives:
* To demonstrate the non-inferiority of the antibody response to meningococcal serogroups A, C, Y, and W after a single dose of MenACYW Conjugate vaccine or Nimenrix® in toddlers who either were meningococcal vaccine naïve or had received monovalent MenC vaccination during infancy.
* To demonstrate the non-inferiority of the antibody response to meningococcal serogroups A, C, Y, and W after a single dose of MenACYW Conjugate vaccine or Nimenrix® in meningococcal vaccine naïve toddlers.
Secondary Objectives:
* To compare the antibody responses (geometric mean titers [GMTs]) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by serum bactericidal assay using human complement (hSBA) in toddlers who either were meningococcal vaccine naïve or had received monovalent MenC vaccination during infancy.
* To compare the antibody responses (GMTs) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by hSBA in meningococcal vaccine naïve toddlers.
* To compare the antibody responses (GMTs) to meningococcal serogroups A, C, Y, and W after a dose of MenACYW Conjugate vaccine or Nimenrix® as measured by hSBA in toddlers who received monovalent MenC vaccination during infancy.

开始日期2017-02-24

申办/合作机构

Sanofi Pasteur SA

NCT00862277

/ CompletedN/A

Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier

To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier

开始日期2008-12-01

申办/合作机构

Sanofi Pasteur SA

NCT00483574

/ Completed临床3期

Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers

This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered in the US.
Safety Objective:
To describe the safety profile of two doses of Menactra® Vaccine.

开始日期2007-05-01

申办/合作机构

Sanofi Pasteur SA

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的临床结果

登录后查看更多信息

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的转化医学

登录后查看更多信息

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的专利（医药）

登录后查看更多信息

项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的文献（医药）

2021-08-01·Journal of clinical pharmacy and therapeutics4区 · 医学

Improving meningococcal MenACWY and 4CMenB/meningococcal group B vaccine‐related health literacy in patients: Importance of readability of pharmaceutical Patient Leaflets

4区 · 医学

Article

作者: Moore, Peter JA ; Millar, Beverley C. ; Moore, John E. ; Brennan, Orlaith C. ; Nutt, Thomas W.

WHAT IS KNOWN AND OBJECTIVE:

Patient information leaflets (PILs) or Patient Leaflets (PLs) formally accompany dispensed medicines and are intended to provide the patient with information on how to use the medicine safely. To date, there have been no studies that have examined the readability of meningococcal vaccine patient-facing information, including information contained within the vaccine PIL. Given the role of pharmacists in presenting PILs to patients, it was, therefore, the aim of this study to quantitatively analyse the readability of Patient Leaflets, which accompany licensed meningococcal vaccines in the UK and US and to compare PILs to vaccine pharmaceutical manufacturers' summary of product characteristics (SPC), as well as other patient-facing vaccine-related information.

METHODS:

Five sources of meningococcal vaccine information were examined for the licensed meningococcal vaccines in the UK (Bexsero, Menveo, Menitorix, Trumenba, Nimenrix & NeisVac-C) and in the United States (Bexsero, Menveo, Trumenba, Menactra, Menomune-A/C/Y/W-135, Menquadfi), including as follows: (i) SPC (Electronic Medicines Compendium, UK), (ii) Package Insert (FDA; USA), (iii) Patient Leaflet (Electronic Medicines Compendium, UK), (iv) Vaccine pharmaceutical websites and (v) government web resources. Readability was examined employing 10 readability metrics, including the Flesch Reading Ease and the Flesch-Kincaid Grade level.

RESULTS AND DISCUSSION:

The information source with the greatest readability scores was the UK Patient Leaflet, which had a mean Flesch Reading Ease score of 58.1 and a mean Flesch-Kincaid Grade score of 7.3, followed by the US Department of Health & Human Services patient-facing website for vaccines (55.9 & 8, respectively), followed by the US Centers for Disease Control and Prevention Vaccine Information Statement (47.3 & 9.4, respectively). Pharmaceutical patient-facing websites for meningococcal vaccines had mean scores of 44.6 and 9.9, respectively. When compared with UK Patient Leaflets, pharmaceutical websites were statistically different with poorer readability with both Flesch Reading Ease and Flesch-Kincaid Grade Level indices (p = 0.02 & p = 0.04, respectively).

WHAT IS NEW AND CONCLUSION:

Pharmaceutical meningococcal vaccine PILs were easily read and had statistically significant good readability scores in comparison with vaccine SPCs and US Package Inserts, pharmaceutical product websites and other government patient-facing meningococcal vaccine information. Preparation of patient-facing materials of a complex topic, such as describing meningococcal vaccines, is difficult to accomplish. Although there is a plurality of sources of information through websites and social media, PILs are one of the few sources that are provided directly to patients. This underpins the potential importance of PILs and the importance of their readability. Adoption of readability calculators and scrutiny of materials for their readability will help authors develop materials with improved understanding for vaccine recipients, potentially leading to improved health literacy and vaccine uptake. Renewed efforts should be sought to promote the information within the PIL, thereby maximizing the value of this resource with vaccine recipients, their carers and family.

2010-10-01·BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy3区 · 医学

Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)

3区 · 医学

Review

作者: Deeks, Emma D

Menveo is a quadrivalent meningococcal polysaccharide conjugate vaccine containing the four Neisseria meningitidis capsular polysaccharides, A, C, W135, and Y, each conjugated to the mutant diphtheria toxin, known as crossreactive material 197 (CRM(197)). Administration of a single dose of the Menveo vaccine elicited a strong immune response against all four vaccine serogroups in adolescents and adults in randomized, single- or multicenter, phase II or III trials. In adolescents, Menveo was generally more immunogenic against vaccine serogroups than the polysaccharide conjugate vaccine Menactra or the unconjugated polysaccharide vaccine Menomune, in terms of seroresponse and/or seroprotection rates and geometric mean titers (GMTs) 1 month post-vaccination in two phase II or III studies. In two phase III trials in adults aged 19-55 years, the immunogenicity of Menveo was generally noninferior or superior to that of Menactra against all four vaccine serogroups, with regard to seroresponse/seroprotection rates, and GMTs 1 month after vaccination. Moreover, an exploratory arm of one of these studies suggested Menveo was at least as immunogenic as Menomune in adults aged 56-65 years. Longer term, the immunogenicity of Menveo persisted for 12-22 months post-vaccination in the adolescent studies, with the vaccine generally remaining at least as immunogenic as Menactra or Menomune. Coadministration of Menveo with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine or Tdap and human papillomavirus vaccines generally did not affect the immunogenicity of these vaccines in adolescents and young adults in two additional randomized, single- or multicenter, phase III studies. The tolerability profile of Menveo was generally similar to that of the comparator vaccines Menactra or Menomune in adults and adolescents, and few Menveo recipients experienced serious adverse events within 30 days or 6 months post-vaccination.

2005-11-04·Human vaccines

Safety and Immunogenicity of a Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Children Aged 2 to 10 Years in Chile

Article

作者: Ryall, Robert ; Pina, Miriam ; Bassily, Ehab ; Lagos, Rosanna ; Papa, Thomas ; Munoz, Alma

Immune responses to meningococcal conjugate (Menactra; MCV-4) and plain polysaccharide (Menomune-A/C/Y/W-135; PSV-4) vaccines against serogroups A, C, Y, and W-135 were assessed in 220 of 1037 Chilean children aged 2 to 10 years participating in a comparative safety trial. Both vaccines were generally well tolerated. Geometric mean serum bactericidal antibody (SBA) titers 28 days postvaccination were comparable in both groups for all four serogroups. Seroconversion was evident in > 97% of MCV-4 and > 90% of PSV-4 vaccinees who tested seronegative at baseline. Menactra safely induced broad and robust immune responses against serogroups A, C, Y and W-135 in this population.

项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的新闻（医药）

2024-04-26

·药智网

流脑疫苗市场的新突破

在出生人口继续减少，流脑疫苗被纳入免疫规划免费产品的情况下，康希诺用于儿童流脑结合疫苗销售收入却较去年同期增长266%。流脑疫苗市场为何颠覆市场预期？01 接种率持续提升脑膜炎可由细菌、真菌、病毒等因素引起，其中细菌性脑膜炎（bacterial meningitis，BM）是最常见、危险及疾病负担最高的脑膜炎类型。肺炎链球菌（Streptococcus pneumoniae，SP）、脑膜炎奈瑟菌或称脑膜炎球菌（Neisseria meningitidis，NM））及B型流感嗜血杆菌（Hib）是世界范围内引起BM的三大致病菌。其中由NM引起的流脑具有发病急、进展快、传染性强、隐性感染率高、病死率高等特点。全球范围内流脑病死率超过10%，致残率高，疾病负担严重。引起流脑病例的NM血清群主要为A、B、C、W、Y和X血清群，合计占比达95%。目前A群流脑病例构成总体呈减少趋势，C群流脑病例构成呈先增加后减少趋势，B、W和其他血清群（包括未分群）流脑病例的构成则呈上升趋势。全球及中国脑膜炎发病率呈逐年下降的趋势。从地区分布来看，脑膜炎发病率最高的国家是印度，其次为巴西。脑膜炎疾病负担最重的是撒哈拉以南非洲地区，即非洲脑膜炎带。从患病人数上看，2019年全球脑膜炎患者约768万，其中印度脑膜炎患者人数最多为210万，中国脑膜炎患者约有21万。世卫组织制定了“到2030年战胜脑膜炎”全球路线图，在此目标下，预计未来预防细菌性脑膜炎疫苗的接种率将持续提升，全球脑膜炎患者人数将呈下降趋势。图1全球及主要国家脑膜炎患病人数（单位：万）数据来源：药智数据，药智咨询整理02 多价流脑结合疫苗为主流产品经调研，截至2024年1月，按品牌（活性成分+企业）计，全球已上市流脑疫苗共有37个（见图2）。由辉瑞研发的Penbraya是全球首款、也是唯一一款五价疫苗（ABCWY），该疫苗于2023年10月获FDA批准上市，用于在10至25岁人群中预防由A、B、C、W和Y血清型脑膜炎双球菌引起的侵袭性疾病。由印度血清研究所研发的MenFive是第一款适合非洲使用的五价脑膜炎球菌结合疫苗（ACYWX），已获得世界卫生组织（WHO）的资格预审。由赛诺菲巴斯德研发的Menomune为全球首款ACYW群脑膜炎球菌多糖疫苗，不过赛诺菲巴斯德已于2017年发布Menomune的停产声明。全球已上市2款B群脑膜炎球菌疫苗，分别为辉瑞的Trumenba和葛兰素史克的Bexsero，中国尚无B群脑膜炎球菌疫苗上市。中国已上市流脑疫苗按品牌（活性成分+企业）计共有23个，包括ACYW群脑膜炎球菌结合疫苗1个、ACYW群脑膜炎球菌多糖疫苗7个、A群C群脑膜炎球菌结合疫苗6个、A群C群脑膜炎球菌多糖疫苗5个、A群脑膜炎球菌多糖疫苗4个。2021年12月，康希诺自主创新研发的四价流脑结合疫苗曼海欣（ACYW135结合疫苗）正式获国家药监局批准上市，成为我国首款获批上市的4价流脑结合疫苗。图2 全球及中国批准上市的流脑疫苗-按品牌计数据来源：药智数据，药智咨询整理全球在研流脑疫苗共有22个。其中ABCWY群脑膜炎疫苗3个、AC-Hib联合疫苗1个、ACYW结合疫苗10个、ACYW多糖疫苗1个、Hib疫苗2个、AC结合疫苗2个、AC多糖疫苗1个、A群多糖疫苗1个。整体来看，四价流脑结合疫苗、B群疫苗和ABCWY群脑膜炎疫苗在研产品较多。国内在研管线方面，已有4家企业的ACYW群结合疫苗处于临床Ⅲ期阶段；而B群疫苗仅有北京智飞绿竹的重组B群脑膜炎球菌疫苗（大肠杆菌）处于临床阶段；另外国内暂无五价流脑疫苗处于临床阶段。预计未来国内ACYW结合疫苗竞争较激烈，B群脑膜炎球菌疫苗竞争较小。03 市场规模有所下降，但目标人群支付能力提高2022年流脑疫苗市场规模同比2021年下降幅度较大，销售额同比下降35.38%，批签发量同比下降36.05%。在供应端，规模较大的沃森生物在2022年，供应大幅减少，AC结合疫苗和ACYW135多糖疫苗无批签发，AC多糖疫苗批签发量下降66%，年报显示是因为公司推动双价HPV疫苗和ACYW135多糖疫苗的世界卫生组织预认证（WHO-PQ）工作，项目整改等原因进行了设备改造，加之相关产品生产计划的调整，导致部分疫苗产品批签发数量下降较大。在需求端，近几年出生人口下降幅度较大，2022年中国出生人口首次跌破1000万，带来流脑疫苗需求的下降。图3 中国流脑疫苗总体市场规模及发展趋势--按销售额计图4 中国流脑疫苗总体市场规模及发展趋势--按批签发量计数据来源：药智数据，药智咨询整理注：销售额：药智数据库收录的各产品中标价中位数*批签发量；批签发量：2018年-2020年的数据来源中检院批签发公布信息，2021年和2022年的数据来源于企业年报，无年报披露的数据根据批签发次数和过往批签发量测算。国内曾上市AC-Hib联合疫苗，适用对象为2月龄至5周岁儿童，主要用于同时预防A群、C群脑膜炎球菌以及b型流感嗜血杆菌引起的脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、会厌炎等感染性疾病。该疫苗是智飞绿竹的独家产品，2018年销售额达17.57亿元，为该领域中销售额最高的产品。但是2020年注册批件到期后药监局给出了不予再注册审批意见。目前国内尚无AC-Hib联合疫苗在售，智飞生物、欧林生物AC-Hib冻干疫苗在研，该品种再次上市后市场规模可能会快速增长。AC多糖疫苗、A群多糖疫苗为免疫规划疫苗，批签发量较高，但是近5年这两类疫苗的批签发量和销售额都处于下降趋势。而AC结合疫苗、ACYW135多糖疫苗、ACYW135结合疫苗这三类自费疫苗，在整体出生人口下降的背景下，销售额和批签发量都处于增长趋势，说明家长对儿童的健康重视程度高，对效果好的产品需求大，支付能力也在提高。图5 流脑疫苗品种市场分布数据来源：药智数据，药智咨询整理04 结语脑膜炎疫苗在国内还存在较大未满足需求。（1）目前免疫规划内的脑膜炎疫苗品种较少且存在有效性不足的情况，而非免疫规划疫苗由于价格较贵、接种意识等原因，其接种率偏低，还存在较大发展潜力；（2）中国目前尚无B群脑膜炎球菌疫苗获批上市，但B群菌株已成为最主要的流行血清群，因此亟需开发B群脑膜炎球菌疫苗产品。声明：本内容为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 八角转载开白 | 马老师 18996384680（同微信）如需定制医药咨询服务，请扫描下方二维码咨询！阅读原文，是受欢迎的文章哦

上市批准疫苗临床研究

100 项与 A/ C/ Y/ W-135群脑膜炎球菌多糖联合疫苗(Sanofi) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎球菌感染	法国	Aventis Pasteur MSD SNC	2002-03-17
脑膜炎球菌感染	意大利	Aventis Pasteur MSD SNC	2002-03-17
侵袭性脑膜炎球菌病	美国	Sanofi Pasteur, Inc.	1999-12-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流行性脑脊髓膜炎	临床3期	美国	Sanofi Pasteur SA	2006-12-01
流行性脑脊髓膜炎	临床3期	波多黎各	Sanofi Pasteur SA	2006-12-01
脑膜炎	临床2期	英国	Sanofi Pasteur SA	2003-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02955797 (CTgov)	临床3期	流行性脑脊髓膜炎	918	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) (Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine)	鑰壓網糧繭簾顧鏇憲製 = 壓獵窪衊鏇齋範簾鏇繭淵廠蓋鑰鏇鹽製衊鹽壓 (蓋遞淵餘願襯鹹艱艱鏇, 衊觸鏇壓鏇製選積襯網 ~ 顧製壓築鑰範網鑰夢鹹) 更多	-	2020-06-09
				Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine (Group 2 (Meningococcal Vaccine-Naive): Nimenrix®)	鑰壓網糧繭簾顧鏇憲製 = 範鬱憲鑰齋構窪選糧夢淵廠蓋鑰鏇鹽製衊鹽壓 (蓋遞淵餘願襯鹹艱艱鏇, 餘鹽顧夢築範鏇齋願艱 ~ 齋齋襯簾醖選鏇淵鏇餘) 更多
NCT00483574 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	1,378	Routine paediatric vaccine - Hepatitis A+Routine paediatric vaccine - Pneumococcal conjugate (PCV)	餘願觸壓齋窪餘淵範願 = 齋獵衊遞鏇範淵繭廠網廠構簾築齋壓遞簾艱淵 (廠獵艱窪餘觸願獵淵憲, 鹽鹽醖壓襯廠繭齋鑰糧 ~ 範積壓觸範膚餘鬱鬱夢) 更多	-	2011-07-06
NCT00422292 (CTgov)	临床3期	流行性脑脊髓膜炎	1,664	Menactra (Group 1: Menactra® at 9 and 12 Months)	簾積構鑰蓋餘壓鑰積願(廠積積繭糧鹹衊製鏇繭) = 繭艱窪製艱淵獵艱遞憲製鏇淵膚願糧鹹鹹夢膚 (築選憲壓衊膚糧範構築, 簾構觸積顧選遞膚窪簾 ~ 顧襯夢選齋觸糧蓋獵鑰) 更多	-	2011-06-02
				MMRV+Menactra (Group 2: Menactra® at 9 Months; Menactra® + MMRV at 12 Months)	製鬱顧選遞餘餘鹹夢鑰 = 鏇顧構鑰衊衊壓壓夢廠壓窪鹹艱遞鑰齋壓繭鏇 (糧糧膚顧鏇蓋窪艱鹽鹹, 衊蓋積艱願鏇獵鹽齋顧 ~ 積鹹鏇願獵願鏇構齋鑰) 更多
NCT00771849 (CTgov)	临床2期	脑膜炎 \| 脑膜炎球菌感染	103	Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra® Vaccine Group)	餘醖蓋鹽遞積選蓋艱鏇(艱遞範齋壓蓋遞窪夢願) = 範構觸築製繭齋蓋襯夢蓋壓構膚選選製鬱衊膚 (獵繭憲淵積淵餘壓網範, 衊構製構願簾積窪遞餘 ~ 齋醖繭壓顧鑰顧艱醖製) 更多	-	2009-04-24
				Haemophilus Influenzae Type b (Hib) vaccine (Hiberix® Vaccine Group)	餘醖蓋鹽遞積選蓋艱鏇(艱遞範齋壓蓋遞窪夢願) = 獵獵繭鑰製醖範繭範選蓋壓構膚選選製鬱衊膚 (獵繭憲淵積淵餘壓網範, 鑰艱鑰膚醖襯膚壓選餘 ~ 餘獵廠憲築淵膚襯獵觸) 更多